It is a link for moving within the page.

  1. HOME
  2. About Otsuka
  3. News Releases
  4. 2016
  5. Antipsychotic ABILIFY Gains Approval in Japan for the Additional Indication of Irritability Associated with Pediatric Autism Spectrum Disorder

September 28, 2016

Otsuka Pharmaceutical Co., Ltd.

Pharmaceuticals

Antipsychotic ABILIFY Gains Approval in Japan for the Additional Indication of Irritability Associated with Pediatric Autism Spectrum Disorder

Otsuka Pharmaceutical Co., Ltd. on September 28, 2016 obtained regulatory approval in Japan of the antipsychotic drug ABILIFY tablet (generic name aripiprazole) for the additional indication of irritability associated with pediatric autistic spectrum.
In addition regulatory approval was granted for ABILFY tablet in a new, 1mg starting dosage form.


Information in this news release was current as of the original release date.

Latest Pharmaceutical Business related News Releases

Most Recent Releases